PomDoctor Limited filed a Form 6-K on November 6, 2026, disclosing that it received written notification from Nasdaq on November 5, 2026, confirming the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

Key Highlights

  • Compliance restored: Nasdaq confirmed on November 5, 2026, that PomDoctor Limited has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).
  • Hearing cancelled: The hearing before the Nasdaq Hearings Panel, previously scheduled for November 12, 2026, has been cancelled as a result of the compliance confirmation.
  • Continued listing: According to the filing, the company's securities will continue to be listed and traded on the Nasdaq Global Market.
  • Press release issued: On November 6, 2026, the company issued a press release announcing receipt of the Nasdaq notification, furnished as Exhibit 99.1 to the filing.
  • Signed by CEO: The filing was signed by Zhenyang Shi, Chairman and Chief Executive Officer of PomDoctor Limited.

PomDoctor Limited Resolves Nasdaq Bid Price Deficiency, Cancels Scheduled Hearing

PomDoctor Limited (NASDAQ:POM), a foreign private issuer headquartered in Guangzhou, People's Republic of China, reported in its Form 6-K for the month of November 2026 that Nasdaq's Listing Qualifications Staff issued a written notification on November 5, 2026, confirming the company "has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1)" and "is therefore in compliance with the continued listing requirements of the Nasdaq Global Market," according to the filing.

As a direct consequence of this confirmation, the filing disclosed that a hearing before the Nasdaq Hearings Panel that had been scheduled for November 12, 2026, has been cancelled. The company stated that its securities will continue to be listed and traded on the Nasdaq Global Market. The filing did not specify how or when the minimum bid price deficiency originally arose, nor did it detail the steps taken to regain compliance.

On the same date as the filing, November 6, 2026, the company issued a press release announcing the receipt of the Nasdaq notification. That press release was furnished as Exhibit 99.1 to the Form 6-K. The filing noted that the information contained in the report, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The report was signed by Zhenyang Shi in his capacity as Chairman and Chief Executive Officer.

What Was Disclosed

PomDoctor Limited disclosed via Form 6-K that Nasdaq confirmed on November 5, 2026, that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), resulting in the cancellation of a previously scheduled Nasdaq Hearings Panel hearing.